Gaynor B D, Holbrook K A, Whitcher J P, Holm S O, Jha H C, Chaudhary J S P, Bhatta R C, Lietman T
The Francis I Proctor Foundation and the Department of Ophthalmology, University of California, San Francisco, 94143, USA.
Br J Ophthalmol. 2003 Feb;87(2):147-8. doi: 10.1136/bjo.87.2.147.
To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma.
A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year after administering a single dose of azithromycin to treat trachoma in a village in Nepal.
S pneumoniae was isolated from 50 (86%) of 57 nasopharyngeal cultures and no resistance to azithromycin was detected.
The authors were unable to demonstrate that mass azithromycin therapy for trachoma produced macrolide resistant S pneumoniae that persists until the next scheduled annual treatment.
确定在每年接受大规模阿奇霉素用于治疗沙眼的地区,对大环内酯类耐药的肺炎链球菌是否会成为一个主要问题。
在尼泊尔一个村庄对单剂量阿奇霉素治疗沙眼1年后的鼻咽部肺炎链球菌分离株进行阿奇霉素敏感性横断面调查。
从57份鼻咽部培养物中的50份(86%)分离出肺炎链球菌,未检测到对阿奇霉素的耐药性。
作者未能证明大规模阿奇霉素治疗沙眼会产生持续至下一次预定年度治疗的大环内酯类耐药肺炎链球菌。